Quantcast

Maverix Strengthens Strategic Co-Marketing Alliance With QIAGEN

April 1, 2014

Integration of Ingenuity® Pathway Analysis and Maverix Analytic Platform Streamlines Biological Interpretation of RNA-seq Studies

SAN MATEO, Calif., April 1, 2014 /PRNewswire/ — Maverix Biomics Inc. today announced that the company has extended its strategic co-marketing agreement with QIAGEN by offering additional technology that enables researchers to transition from raw sequence data to the understanding of complex biological systems at the core of life science research. QIAGEN’s Ingenuity® Pathway Analysis (IPA®) combined with the Maverix Analytic Platform simplifies the analysis and interpretation of RNA-seq data, accelerating research and extending the instrument-to-insight workflow. This added integration strengthens the existing relationship between the two companies which announced the seamless integration of QIAGEN’s Ingenuity® iReport(TM) and Maverix Analytic Platform in November 2013.

More than 10,000 peer-reviewed journal publications have cited IPA, the industry’s gold standard for biological analysis and interpretation, in reference to gene expression data analysis. This integration further streamlines the data analysis and interpretation workflow for state-of-the-art next-generation sequencing (NGS) technology.

The powerful combination of the Maverix Analytic Platform and QIAGEN’s technology allows researchers to simplify the interpretation of raw NGS data by providing easy, three-step, push-button data analyses that result in meaningful and actionable insights. The integrated approach will accelerate researchers’ ability to rapidly process and quantitate millions of raw sequencing reads into biologically meaningful gene expression patterns, and produce a clearer understanding of what disease-associated pathways may be affected, such as those altered in cancer progression.

“By extending our relationship with Maverix, we are providing a seamless workflow from raw sequencing files to biological interpretation, which will accelerate the pace of insights researchers gain from their RNA-seq experiments,” said Debra Toburen, Director of Product Management, at QIAGEN Redwood City. “The addition of IPA complements Ingenuity iReport and expands the options for analyzing their sequencing data.”

“Providing life science researchers with this integrated solution for RNA-seq analysis and interpretation unlocks the potential for discovery within the huge volume of under-studied biological samples,” said Dave Mandelkern, co-founder and CEO of Maverix Biomics.

Maverix and QIAGEN have planned a series of joint marketing initiatives to promote the strategic relationship, including conducting joint webinars and presentations at the American Association for Cancer Research (AACR) Annual Meeting 2014 in San Diego, California. This new integrated workflow will be demonstrated in a complementary webinar titled “Maverix to Ingenuity: Find biological insights from RNA-seq data faster” on Wednesday, April 2, 2014 at 9:00 AM PDT. Interested parties can register at https://attendee.gotowebinar.com/register/9007698790007504386. In addition, demonstrations of the integrated workflow can be seen at AACR in the Maverix Biomics Booth #2849.

About the Maverix Analytic Platform
Maverix Analytic Platform is a cloud-based solution designed for use directly by life sciences researchers who may not have software or bioinformatics expertise. It leverages proven, open-source algorithms and applications developed at leading academic and research centers. After loading sequence data from any organism (human, animal, plant, or microbe), researchers are able to immediately perform analysis with reliable, scientifically recommended configurations, as cited in peer- reviewed journal publications. Visualization is provided through a variety of integrated graphical tools, including the UCSC Genome Browser, the world’s most widely used genome browser.

About Maverix Biomics
Based in San Mateo, CA and backed by leading venture capital firms and Silicon Valley investors, Maverix Biomics, Inc. provides researchers with a cloud-based platform to manage, analyze, and visualize genomic data, build Communities of Discovery, and place their data in context with the latest public data from the full spectrum of life, including human, plant, animal, or microbial organisms. For more information, visit www.maverixbio.com.

SOURCE Maverix Biomics


Source: PR Newswire



comments powered by Disqus